Economic aspects of medical erectile dysfunction therapies
- 1 March 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (3) , 257-263
- https://doi.org/10.1517/14656566.3.3.257
Abstract
The introduction of safe and effective oral therapies has changed the significance of erectile dysfunction (ED) forever. Seldom has a new drug changed the landscape of pharmacotherapy in so many ways as sildenafil (Viagra, Pfizer). This article highlights the various oral, intracavernosal and intraurethral therapies currently available for ED and evaluates the socio-economic impact of each method.Keywords
This publication has 16 references indexed in Scilit:
- Erectile dysfunction in general medicine practice: prevalence and clinical correlatesInternational Journal Of Impotence Research, 2000
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997
- A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadilUrology, 1996
- Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile DysfunctionNew England Journal of Medicine, 1996
- Effect of Apomorphine on Penile Tumescence in Men with Psychogenic ImpotenceJournal of Urology, 1991
- Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literatureArchives of Sexual Behavior, 1990
- Prostaglandin 15‐hydroxydehydrogenase Activity in Human Penile Corpora Cavernosa and its Significance in Prostaglandin‐mediated Penile ErectionBritish Journal of Urology, 1989
- Intracavernous Injection of Prostaglandin E1 for the Treatment of Erectile ImpotenceJournal of Urology, 1989
- Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic ImpotenceJournal of Urology, 1985